NRx Pharmaceuticals (NASDAQ: NRXP), has submitted an Abbreviated New Drug Application (ANDA) to the FDA for NRX-100, its preservative-free intravenous ketamine ...
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is executing a dual growth strategy focused on expanding its national network of ...
NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing ...
NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, has engaged IBN to ...
Medicinal marijuana products that are legal at the state level will see looser federal regulation under an order the U.S. Department of Justice published Thursday, while…
NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a positive Discipline Review Letter from the FDA Office of Generic Drugs covering quality-related aspects of its…
Lifestyle modifications, particularly increased physical activity, have a host of benefits. New research suggests they may ease or even reverse symptoms of Parkinson's…
RESEARCH TRIANGLE PARK, N.C., April 22, 2026 /PRNewswire/ -- Access to medications for opioid use disorder (OUD) increased substantially among Medicaid beneficiaries…
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP ) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central…
Research Snipers Addiction treatment no longer follows a single, rigid path. Women navigating recovery today often need... The post 5 Modern Addiction Treatment Options…
(The Center Square) – Some say President Donald Trump’s new executive order on psychedelics goes too far, while others say it’s a good first step, but more action is…
Strasbourg, France and Charleroi, Belgium, 22 April 2026 (0830 CET) – Elkedonia, a biotech company pioneering a novel neuroplastogen approach to develop therapeutics for…
NRx Pharmaceuticals has received a positive Discipline Review Letter from the FDA Office of Generic Drugs and completed a supportive meeting with Generic Drug…
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP ) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central…
A renewed spotlight is forming around a group of small-cap healthcare companies as U.S. policy shifts toward accelerating research into psychedelic-based therapies for…
LONDON & NEW YORK--(BUSINESS WIRE) $CMPS Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based…
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies Company's clinical research operations and therapist training programs directly positioned to…
In the trial’s overall (intent-to-treat) study population, daraxonrasib showed a median overall survival (OS) of 13.2 months, nearly double the 6.7 months demonstrated…
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science…
Kamal Nahas is a freelance contributor based in Oxford, U.K. His work has appeared in New Scientist, Science and The Scientist, among other outlets, and he mainly covers…
President Donald Trump signed an executive order to expedite the FDA review of psychedelic drugs for treating PTSD and traumatic brain injuries in military veterans,…